Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
621-640 of 1,307 trials

Cancer Treatment: PET Tracers and T Cell Activity

We are studying how two PET tracers relate to T cell changes in cancer patients before surgery. This research may help us understand T cell activation and its impact on tumor response.

Breast CancerEsophageal CancerMelanoma3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Soft-Tissue Sarcoma: Intensified Chemotherapy Study

We are investigating whether adding extra chemotherapy cycles helps high-risk patients with resectable soft-tissue sarcomas have better outcomes after surgery. This study compares the effects of different chemotherapy regimens on survival rates.

Resectable Non-Metastatic Soft-Tissue Sarcoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementOncology

Geographic Atrophy: Pozelimab and Cemdisiran Study

We are investigating whether a new treatment combining pozelimab with cemdisiran helps slow the progression of geographic atrophy in adults. This study aims to understand its effects on vision and safety compared to cemdisiran alone.

Geographic Atrophy from Age-Related Macular Degeneration>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicineOphthalmology

Colorectal Cancer: Intermittent vs. Continuous Treatment with Panitumumab

We are studying whether an intermittent treatment of Panitumumab with FOLFIRI is as effective as continuous treatment for patients with metastatic left-sided colorectal cancer. The trial also aims to assess safety and quality of life for participants.

Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Guselkumab for Kids with Inflammatory Conditions

We are studying the long-term safety of guselkumab in children with ulcerative colitis, Crohn’s disease, or juvenile psoriatic arthritis. This research aims to ensure the medication is safe for young patients.

Crohn's DiseaseJuvenile Psoriatic ArthritisUlcerative Colitis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementDermatologyGastroenterologyRheumatology

Ulcerative Colitis: Oral Mesalazine Treatment

We are studying an oral medication for people with mild to moderate ulcerative colitis to see if it helps induce remission of symptoms. The trial will assess various measures of improvement after treatment.

Ulcerative Colitis3-6 monthsConfirmation phase (III)Standard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Hamstring Injury: Hyperbaric Oxygen Therapy Study

We are investigating whether hyperbaric oxygen therapy helps athletes and military personnel recover faster from hamstring injuries. The study will also look at safety and changes in injury over time.

Hamstring InjuryConfirmation phase (III)No PlaceboStandard MedicinesOrthopedics and Traumatology

Crohn's Disease: Upadacitinib for Children

We are studying the effects of Upadacitinib in children with active Crohn's disease who haven't had success with other treatments. The goal is to see if it helps them achieve better health outcomes.

Crohn's Disease>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Esophageal Cancer: Ifinatamab Deruxtecan Study

We are studying Ifinatamab Deruxtecan in patients with advanced esophageal squamous cell carcinoma who have already been treated. The goal is to see if it works better than standard chemotherapy options.

Esophageal Squamous Cell CarcinomaConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Ulcerative Colitis: Tofacitinib for Children

We are studying whether the oral medication tofacitinib can help children with moderately to severely active ulcerative colitis achieve remission. The trial will also look at how well the medication works and how it is accepted by young patients.

Ulcerative Colitis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Heart Failure: Vicadrostat and Empagliflozin Study

We are testing if the combination of vicadrostat and empagliflozin helps people with heart failure feel better and reduces serious heart-related events. This study is for individuals with specific heart failure symptoms and heart function.

Heart FailureConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Fabry Disease: Venglustat Tablets

We are studying whether venglustat can improve heart health in adults with Fabry disease compared to standard treatments. The trial also looks at its effects on kidney function and overall well-being.

Fabry's Disease1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCardiologyHematologyInternal Medicine

Atrial Fibrillation: New Drug Treatment After Stent Surgery

We are studying whether a simpler medication regimen can safely prevent blood clots and serious heart issues in patients with irregular heartbeat after coronary stent implantation. This trial compares it to the current standard treatment involving multiple medications.

Acute Coronary SyndromeAtrial FibrillationAtrial Flutter>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Constipation Prevention in Critically Ill Children: PEG3350+E Treatment

We are studying whether a special solution can help prevent constipation in critically ill children. The trial also looks at the safety of this treatment and compares stool consistency in different patient groups.

Constipation≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyPediatrics

Nephrotic Syndrome: Rituximab Treatment Comparison

We are comparing two Rituximab treatment plans for adults with relapsing nephrotic syndrome. The goal is to find out which regimen better prevents relapses and improves quality of life.

Nephrotic Syndrome1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyNephrology

Metastatic Colorectal Cancer: Regorafenib with Chemotherapy

We are studying whether combining Regorafenib with metronomic chemotherapy and low-dose aspirin helps patients with chemo-resistant metastatic colorectal cancer live longer without disease progression. We will also look at quality of life and treatment side effects.

Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Severe von Willebrand Disease: New Treatment Study

We are testing a new treatment for children with severe von Willebrand Disease to see if it helps control bleeding episodes and is safe during surgeries. The study will compare this treatment with and without an existing medication.

Von Willebrand's Factor Deficiency>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyPediatrics

Metastatic Colorectal Cancer: Sacituzumab Govitecan Study

We are investigating a new treatment for patients with metastatic colorectal cancer who have not responded to standard care. The study aims to see if this new drug can improve survival and response rates compared to existing treatments.

Metastatic Colorectal CancerEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyOncology

COVID-19 Treatment: Nirmatrelvir/Ritonavir for Children

We are studying a new oral medication for children with COVID-19 who are at risk of severe illness. The trial will evaluate its safety, how well it works, and how it is tolerated in young patients.

COVID-19Efficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPediatrics

Oxygen Levels at Birth: The HiLo-Trial

We are studying whether giving very low birthweight infants 60% oxygen instead of 30% at birth can improve their development by 18-24 months. This research aims to find the best approach for resuscitating preterm infants.

PrematurityConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteNeurologyPediatrics